Preclinical Data Support GeNeuro Antibody for Treating Sporadic ALS

Preclinical Data Support GeNeuro Antibody for Treating Sporadic ALS

310009

Preclinical Data Support GeNeuro Antibody for Treating Sporadic ALS

New early clinical study results support the potential of GN-K01, an investigational antibody being developed by GeNeuro, as a treatment for amyotrophic lateral sclerosis (ALS). The therapy may enter clinical trials as early as 2022, according to the company. The antibody targets a viral protein, called HERV-K ENV, that was found at high levels in the cerebrospinal fluid or CSF — the liquid surrounding the brain and spinal cord — of sporadic ALS patients. It…

You must be logged in to read/download the full post.